Paid Clinical Trials in Fargo, ND

As of June 2026, 209 paid clinical trials are recruiting in Fargo, North Dakota. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 25, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

209 clinical trials

↓ Download CSV

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

for Chronic Obstructive Pulmonary Disease

Drug: Lunsekimig

66 locations incl. Chandler

Sponsor: Sanofi

Sex: All·Age: 40 - 80

Code: NCT07190209·Phase 3·Recruiting

Apply to this trial

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

for Advanced Pancreatic Carcinoma

109 locations incl. Birmingham

Sponsor: Sameek Roychowdhury

Sex: All·Age: 18+

Code: NCT06906562·Phase 2·Recruiting

Apply to this trial

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

for Cardiovascular Disease

Drug: Olpasiran

205 locations incl. Alexander City

Sponsor: Amgen

Sex: All·Age: 50 - 105

Code: NCT07136012·Phase 3·Recruiting

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

279 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting

Apply to this trial

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

for Relapsing Multiple Sclerosis

Drug: Remibrutinib

38 locations incl. Scottsdale

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 40 - 70

Code: NCT06846281·Phase 3·Recruiting

Apply to this trial

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

for Diabetes Mellitus, Type 2

Drug: Empagliflozin

216 locations incl. Anniston

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07064473·Phase 3·Recruiting

Apply to this trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

for Pancreatic Neuroendocrine Tumor (pNET)

39 locations incl. Birmingham

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06943755·Phase 2, Phase 3·Recruiting

Apply to this trial

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

for Advanced Cancer

6 locations incl. Phoenix

Sponsor: Alliance Foundation Trials, LLC.

Sex: All·Age: 21+

Code: NCT06963723·Recruiting

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

332 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting

Apply to this trial

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

for Moderate Aortic Valve Stenosis

Drug: Ataciguat

66 locations incl. Birmingham

Sponsor: Kardigan, Inc.

Sex: All·Age: 50+

Code: NCT07001800·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

for Hidradenitis Suppurativa

49 locations incl. Birmingham

Sponsor: MoonLake Immunotherapeutics AG

Sex: All·Age: 12+

Code: NCT07007637·Phase 3·Enrolling By Invitation

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

for Hidradenitis Suppurativa

Drug: Ruxolitinib

59 locations incl. Phoenix

Sponsor: Incyte Corporation

Sex: All·Age: 12+

Code: NCT06959225·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

for Atopic Dermatitis

16 locations incl. Lancaster

Sponsor: Inmagene LLC

Sex: All·Age: 18 - 74

Code: NCT07037901·Phase 2·Recruiting

Apply to this trial

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

for Atopic Dermatitis (AD)

2 locations incl. Fargo

Sponsor: LAPIX Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06982352·Phase 1·Recruiting

Apply to this trial

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for Myelodysplastic Syndrome

138 locations incl. Berkeley

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06577441·Phase 2·Recruiting

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

Drug: Venetoclax

112 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting

Apply to this trial

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for Head and Neck Squamous Cell Carcinoma

200 locations incl. Gilbert

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06992427·Phase 3·Recruiting

Apply to this trial

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for Cardiovascular Disease

315 locations incl. Athens

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07000357·Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

for Non-Muscle Invasive Bladder Urothelial Carcinoma

132 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06770582·Phase 2·Recruiting

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

139 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting

Apply to this trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for Prostate Cancer (Adenocarcinoma)

350 locations incl. Anchorage

Sponsor: Canadian Cancer Trials Group

Sex: Male·Age: 18+

Code: NCT06592924·Phase 3·Recruiting

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

17 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

Drug: Cemiplimab

386 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting

Apply to this trial

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

for Age-Related Macular Degeneration

7 locations incl. Fargo

Sponsor: University of Wisconsin, Madison

Sex: All·Age: 50+·Accepts healthy volunteers

Code: NCT06924021·Recruiting

Apply to this trial

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

for Pancreatic Carcinoma

118 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06807437·Phase 3·Recruiting

Apply to this trial

The Minimalist Trial-2

for HPV-Related Oropharynx Squamous Cell Carcinoma

3 locations incl. St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT06702033·Phase 2·Recruiting

Apply to this trial

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for Lung Non-Small Cell Carcinoma

265 locations incl. Jonesboro

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06498635·Phase 3·Recruiting

Apply to this trial

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

for Non-small Cell Lung Cancer

5 locations incl. Lexington

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06731907·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

177 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting

Apply to this trial

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

for Pleuropulmonary Blastoma

76 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT06647953·Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for Clear Cell Renal Cell Carcinoma

414 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06661720·Phase 3·Recruiting

Apply to this trial

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

for Heart Failure

Drug: Dapagliflozin

194 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 40+

Code: NCT06677060·Phase 3·Recruiting

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

Drug: Bevacizumab

658 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

190 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

for Extensive-Stage Small Cell Lung Cancer

Drug: Atezolizumab

20 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06646276·Phase 3·Recruiting

Apply to this trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for Castration-Resistant Prostate Carcinoma

107 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06632977·Phase 2·Recruiting

Apply to this trial

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

for Pyoderma Gangrenosum

20 locations incl. Birmingham

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06624670·Phase 3·Recruiting

Apply to this trial

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for Breast Carcinoma

464 locations incl. Fairbanks

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 18+

Code: NCT06418204·Recruiting

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

Drug: Rituximab

42 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

for NonSegmental Vitiligo

Drug: Ruxolitinib

80 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 2 - 11

Code: NCT06548360·Phase 3·Recruiting

Apply to this trial